Generics Firms Improved Chances Of Winning Pre-ANDA Meetings For Complex Drugs Last Year
Executive Summary
FDA officials said manufacturers of complex generic drugs submitted more approvable requests for pre-submission meetings for FY 2018. Official also clarifies at recent meeting when it's best to request a pre-ANDA meeting and when to submit a controlled correspondence.